Relatlimab-nivolumab combination extends PFS in metastatic melanoma
Source: Healio, March 2021
A trial designed to evaluate the addition of relatlimab to nivolumab for untreated metastatic or unresectable melanoma met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.
Relatlimab (Bristol Myers Squibb) is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody.
